Rznomics, Inc. announced on January 19th that it had signed a three-party business agreement (MOU) with CJ and Batavia Bioscience for cooperation in the production and development of gene therapy products based on virus delivery systems.

Three companies plan to cooperate in the exchange of material and human resources to conduct research and development on the production process of gene therapy products. The companies decided to explore collaboration for mass production in the future commercialization stage,

Batavia is a contract development and manufacturing (CDMO) company based in the Netherlands. CJ acquired Batavia last year to speed up its business in 'health (wellness)' as one of the four future growth engines. They possess process development and manufacturing technology for vaccines and gene therapy products.

Rznomics is a gene therapy development company established in 2017. Based on ribonucleic acid (RNA) substitution enzyme (Trans-Ribozyme), the company is developing gene therapy for anticancer and intractable diseases. The company also plans to transfer its technology to multinational pharmaceutical companies in the future.

“Through this collaboration, we will be able to accelerate the development of next-generation gene therapy products based on our unique platform technology,” said Seong-wook Lee, CEO of Rznomics.

A CJ official said, "Starting with the agreement with Rznomics, we will help domestic bio companies with capabilities to advance into international markets.

Rznomics is pursuing the IPO process with the goal of second half of next year. In Series A and B, it maintained investments of KRW 12 billion and KRW 10.5 billion, respectively.

The government project support totaled KRW 3.3 billion. The series C investment is expected to be completed in the first quarter of this year.